Eplerenone in chronic renal disease: The EVALUATE trial

Hypertension Research

Volumn 33, Issue 6, 2010, Pages 539-540

  Funder, John W ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SODIUM ION; SPIRONOLACTONE;

AGING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG INDUCED HEADACHE; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RENAL PROTECTION; SEX DIFFERENCE; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; SPIRONOLACTONE; YOUNG ADULT;

EID: 77953224808     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.71     Document Type: Note

References (5)

1. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740.
2. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albumi-nuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
3. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
4. Mihaildou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-1312.
5. Funder JW. Aldosterone, sodium and hypertension: lessons from torcetrapib? Hypertension 2010; 55: 221-223.